What stands out

  • A full domestic CAR-T pipeline: eight marketed products by 2026, versus a handful in the US or EU
  • List prices around ¥1.0–1.3 million (roughly US$140,000–180,000) per infusion, against US list prices of roughly $373,000–$525,000
  • Payment experiments — outcomes-based refunds and commercial-insurance deals — pushing patient out-of-pocket far below list price

Why people watch this space

CAR-T therapy — a patient’s own T cells engineered to attack their cancer, then re-infused — is one of the most expensive treatment categories in medicine anywhere. The reason it draws attention in China is arithmetic: China’s approved CAR-T products list at prices that are a fraction of US list prices, and the gap has been widening in China’s favour as domestic manufacturing scales. This page explains the landscape with sourced numbers. It is explicitly not treatment advice — CAR-T is prescribed for specific blood cancers under specific conditions, and eligibility, quality and follow-up questions belong with oncologists.

The approvals

China approved its first CAR-T in 2021 — Fosun Kite’s relma-cel — as Sixth Tone reported at the time, noting that the equivalent treatment cost over US$370,000 in the United States. Since then the pipeline has widened across manufacturers and targets: CARsgen’s zevorcabtagene autoleucel for multiple myeloma followed in 2024, and by mid-2026 Chinese media counted eight marketed CAR-T products. The headline approval came in June 2026: CARsgen’s satri-cel for advanced gastric cancer, the world’s first regulatory approval of a CAR-T for a solid tumour — a class of approval no Western regulator has yet granted.

The prices, sourced

  • China: a peer-reviewed 2024 analysis in Medicine put Chinese CAR-T list pricing between ¥999,000 and ¥1.29 million per infusion — roughly US$140,000–180,000 at prevailing rates. The first product to break the ¥1 million line did so at ¥999,000.
  • United States: FDA-approved CAR-Ts list at US$373,000–530,000 per infusion before hospitalisation costs — Yescarta and Tecartus at $373,000, Kymriah at $475,000, Carvykti at $465,000, and the newest approval at $525,000. A 2026 cost analysis documents how total episode-of-care costs run well past the drug price itself — a caveat that applies in both countries.
  • Downward pressure in China: one domestic manufacturer has signalled a launch price of ¥230,000–250,000 for its next product, attributing the drop to localised, non-customised production. Whether that price materialises is an open question, but the direction is unusual in a specialty where Western prices have only risen.

How patients actually pay

List price is not what many Chinese patients pay. Fosun Kite introduced a nationwide outcomes-based payment plan that refunds up to ¥600,000 — around half the list price — for patients who do not respond, a structure with little parallel in the US market. In 2025, a new national commercial-insurance innovative-drug catalogue included five CAR-T products after price negotiations, with patient out-of-pocket costs expected to fall to around ¥40,000 per dose. No CAR-T had entered the state National Reimbursement Drug List as of September 2025 (peer-reviewed review), which is why the commercial-insurance route matters. Foreign self-pay patients negotiate directly with hospitals’ international departments — at list prices near the figures above.

Read the numbers carefully

  • List prices compare drug product to drug product; they exclude lymphodepletion, hospital stays and complication management, which add materially in both countries.
  • Chinese approvals cover indications defined by Chinese regulators, occasionally with no FDA-approved equivalent anywhere — which is precisely why the space is watched, and why cross-border patients face genuine unknowns in follow-up care back home.
  • “Cheaper” does not mean simple: cell therapies involve apheresis, manufacturing windows and specialised centres; a brief medical trip does not contain one. Visa and stay logistics are in our visa guide; funding logistics in paying for care and insurance coverage — foreign insurers almost never fund planned treatment abroad.
  • For concrete price context on better-documented procedures, see the cost comparisons; for how hospitals actually run, the first-visit guide and our video library.

The honest summary of why people watch: a therapy class that costs US$400,000+ in the United States exists, approved and manufactured, at a third of that price in China — with a solid-tumour first that no other country can claim. Whether that makes it the right option for any individual is a question this site does not answer.